

# *Clinical context of patients commonly referred for renal clearance:*


## *A nephrologist's perspective*

**Prof. Dr. T. Baudoux (HUB, Brussels)**




# What are Nephrons

- The **nephron** is the functional unit of the kidney.
- Each kidney contains about 1,000,000 to 1,300,000 nephrons.
- The nephron is composed of **glomerulus** and **renal tubules**.
- The nephron performs its homeostatic function by **ultra filtration** at glomerulus and **secretion** and **reabsorption** at renal tubules.



# What are the kidney functions ?

- **Regulation** of the following :
  - water and electrolyte balance.
  - acid base balance.
  - arterial blood pressure.
- **Excretion** of metabolic waste products and foreign chemicals.
- **Hormonal Functions** :
  - Secretion of erythropoietin
  - Activation of vitamin D
  - Activation of angiotensinogen by renin .
- **Metabolic Function** :
  - site for gluconeogenesis .




# From « *kidney functions* » to « GFR »...

- In 1951, **Homer Smith** declared that the best way to test kidney function is...

...« *to measure the glomerular filtration rate (GFR) by inulin clearance* »



- Since, we have never left this « glomerulocentric » functional approach...




Today « GFR » is still considered as the « **best** » overall measure of the **kidney's ability to carry out these various functions** »

# What is a « normal » GFR ?

- The glomerular filtration rate (GFR) is equal to the sum of the filtration rates in all of the functioning nephrons.
  - Approximately 180 liters per day (**125 mL/min**) of plasma are filtered
- The normal value for GFR is approximately 90 to 120 mL/min/1.73 m<sup>2</sup> with **important variation** even **among healthy individuals**
  - Age, sex...
- Significance of a declining GFR in patients with kidney disease
  - A fall in glomerular filtration rate (GFR) implies either progression of the underlying disease (CKD) or the development of a superimposed and often reversible problem (AKI)


# Limitations of GFR

- No information on the **cause** of the kidney disease
- No evaluation of albuminuria or hematuria, morphology ...
- GFR do not permit an evaluation of all the « **specific** » functions of the kidneys



# Limitations of GFR

- There is **not an exact correlation** between the loss of **kidney mass** (ie, nephron loss) and the loss of **GFR**.
  - The kidney adapts to the loss of some nephrons by compensatory **hyperfiltration** in the remaining, normal nephrons.
  - Thus, an individual who has lost one-half of total kidney mass will not necessarily have one-half the normal amount of GFR.
- **These concepts have important consequences:**
  - A stable GFR does not necessarily imply stable disease.
  - An increase in GFR may indicate improvement in the kidney disease or may imply a counterproductive increase in filtration (hyperfiltration) due to hemodynamic factors
  - Some patients who have true underlying kidney disease may go unrecognized because they have a normal GFR.





# How to « **measure** » GFR → « **mGFR** »

- The **true glomerular filtration rate (GFR)** cannot be measured **directly** in humans...
  - GFR is measured using clearance of an « **ideal** » substance and is defined as the volume cleared of that substance per time.
  - An ideal filtration marker should be excreted by the kidneys, not be protein-bound, and not be secreted or reabsorbed in the tubules.
- The **gold standard** method is urinary or plasma clearance of an **exogenous filtration marker**.
  - Urinary clearance of **inulin** was described by Homer Smith in 1935, and it is still the gold standard for GFR measurement.
  - Many other **exogenous markers** have been used such as
    - Technetium-99m diethylene- triaminepentaacetic acid (**99mTc-DTPA**)
    - **iothalamate**,
    - Chromium-51 ethylenediaminetetraacetic acid (**51Cr-EDTA**)
    - Iohexol



# How to « **estimate** » GFR → « **eGFR** »

- Methods to measure GFR are laborious, expensive, and not broadly available, and are therefore not appropriate as first-line diagnostic tools.
- In most clinical settings, blood levels of **endogenous filtration markers** are used to estimate GFR

*« To date, despite **ambitious research** to identify a **perfect endogenous filtration marker** that fulfils all criteria, namely being freely filtered and neither secreted nor reabsorbed by the kidney, being inexpensive and measurable by a standardized automated assay and not significantly influenced by other patient characteristics, has been **disappointing** so far »*

- **Creatinine** is still the most commonly used endogenous marker
- Widely available, freely filtered by the glomerulus...
  - ... But subject to extrarenal elimination (gastrointestinal tract), secreted by the renal tubules, generated from muscle mass or diet (cooked meat)

# How to « estimate » GFR → « *eGFR* »


- **Cystatin C** is an alternative endogenous filtration marker
  - It is freely filtered at the glomerulus, is catabolized in the tubules with reabsorption of its metabolites, and undergoes extrarenal elimination to some extent.
  - Cystatin C is not excreted in the urine
  - It is less influenced by non-GFR determinants than creatinine
    - non-GFR determinants of cystatin C include inflammation, smoking, thyroid abnormalities, and fat mass

# How to « estimate » GFR → « *eGFR* »

- **Equations** that estimate GFR are most commonly used in daily practice.
  - Based on plasma creatinine (+/- cystatin C)

## Advantages:

- Inexpensive
- Results are immediately available.



## Disadvantages:

- Rely on endogenous biomarkers, which are confounded by non-GFR determinants:
  - Age, sex, muscle mass, drugs, diet...





# How to « estimate » GFR → « eGFR »

Age	Marker	Reference Method	Standardized Assay	Derivation Study Characteristics	Equation	Comment
<b>Creatinine (eGFR<sub>cr</sub>)</b>						
Adult	Cockcroft-Gault (1976) <sup>a</sup>	mCL <sub>cr</sub>	No	249 men; 0% Black participants (presumed)	$(140 - \text{age} \times \text{weight}) / (72 \times \text{Scr}) \times 0.85$ if female	Underestimates mCL <sub>cr</sub> in older age, obesity, and edematous states
Adult	MDRD Study (2006) <sup>b</sup>	Urinary iohalamate	Yes	983 men/645 women; mGFR 40 mL/min/1.73 m <sup>2</sup> ; age 50.6 y; 12% Black participants	$175 \times \text{Scr}^{-1.154} \times \text{age}^{-0.203} \times 0.745$ if female $\times 1.212$ if Black	Underestimates mGFR in high-normal GFR values
Adult	CKD-EPI eGFR <sub>cr</sub> (2009) <sup>c</sup>	Urinary iohalamate, other mGFR	Yes	4,648 men/3,606 women; mGFR 68 mL/min/1.73 m <sup>2</sup> ; age 47 y; 30% Black participants	$141 \times \min(\text{Scr}/\kappa, 1)^\alpha \times \max(\text{Scr}/\kappa, 1)^{-1.209} \times 0.993^{\text{age}} \times 1.018$ if female $\times 1.159$ if Black   $\alpha = -0.329$ (female); $-0.411$ (male); $\kappa = 0.7$ (female); $\kappa = 0.9$ (male)	Unbiased across range of GFR; recommended in adults
Pediatric	CKiD Schwartz "bedside" (2009) <sup>d</sup>	Plasma clearance of iohexol	Yes	213 boys/136 girls; mGFR 41 mL/min/1.73 m <sup>2</sup> ; age 10.8 y; 15% Black participants	$0.413 \times (\text{height in cm}/\text{Scr})$	Iohexol measurements have since been recalibrated
Pediatric and young adult (age 18-26 y)	Average of CKiD (2009) and CKD-EPI (2009) <sup>e</sup>	Per CKiD 2009 and CKD-EPI 2009 equations			–	Improves eGFR accuracy in young adults; iohexol measurements have since been recalibrated
Pediatric and young adult	CKiD eGFR <sub>cr</sub> U25 (2021) <sup>f</sup>	Plasma clearance of iohexol	Yes	387 boys/231 girls; mGFR 48 mL/min/1.73 m <sup>2</sup> ; age 13 y; 7% Black participants	$K \times \text{height}/\text{Scr}$   K for males 1-11 y, $39 \times 1.008^{(\text{age} - 12)}$ , 12-17 y, $39 \times 1.045^{(\text{age} - 12)}$ , 18-25 y, 50.8; K for females: 1-11 y, $36.1 \times 1.008^{(\text{age} - 12)}$ , 12-17 y, $39 \times 1.023^{(\text{age} - 12)}$ , 18-25 y, 41.4	Improves performance vs CKiD "bedside," especially for age <5 and >18 y
<b>Cystatin C (eGFR<sub>cys</sub>)</b>						
Adult	CKD-EPI eGFR <sub>cys</sub> (2012) <sup>g</sup>	Urinary iohalamate	Yes	3,107 men/2,245 women; mGFR 68 mL/min/1.73 m <sup>2</sup> ; age 47 y; 33% Black participants	$133 \times \min(\text{Scys}/0.8, 1)^{-0.499} \times \max(\text{Scys}/0.8, 1)^{-1.328} \times 0.996^{\text{age}}$ $\times 0.932$ if female	Similar performance to CKD-EPI eGFR <sub>cr</sub> , but decreased impact of age, sex, and race
Pediatric	CKiD Cys (Schwartz "bedside" cystatin C; 2012) <sup>h</sup>	Plasma clearance of iohexol	No	389 boys/254 girls; mGFR 43 mL/min/1.73 m <sup>2</sup>	$70.69 \times S_{\text{cys}}^{0.931}$	Iohexol measurements have since been recalibrated; cystatin C assay not standardized
Pediatric and young adult	CKiD eGFR <sub>cys</sub> U25 (2021) <sup>f</sup>	Plasma clearance of iohexol	Yes	387 boys/231 girls; mGFR 48 mL/min/1.73 m <sup>2</sup> ; age 13 y; 7% Black participants	$K \times 1/\text{Scys}$   K for males 1-14 y, $87.2 \times 1.011^{(\text{age} - 15)}$ , 15-17 y, $87.2 \times 0.960^{(\text{age} - 15)}$ , 18-25 y, 77.1; K for females: 1-11 y, 79.9 $\times 1.004^{(\text{age} - 12)}$ , 12-17 y, 79.9 $\times 0.974^{(\text{age} - 12)}$ , 18-25 y, 68.3	Improves performance vs CKiD "bedside," especially for age <5 and >18 y



# How to « estimate » GFR → « eGFR »

**Table 3 (Cont'd).** Equations Estimating mGFR from Endogenous Filtration Markers With Large Representation of North Americans

Age	Marker	Reference Method	Standardized Assay	Derivation Study Characteristics	Equation	Comment
<b>Creatinine and cystatin C (eGFR<sub>cr-cys</sub>)</b>						
Adult	CKD-EPI eGFR <sub>cr-cys</sub> (2012) <sup>g</sup>	Urinary iothalamate	Yes	3,107 men/2,245 women; mGFR 68 mL/min/1.73 m <sup>2</sup> ; age 47 y; 33% Black participants	$135 \times \min(\text{Scr}/\kappa, 1)^{\alpha} \times \max(\text{Scr}/\kappa, 1)^{-0.601} \times \min(\text{Scys}/0.8, 1)^{-0.375} \times \max(\text{Scys}/0.8, 1)^{-0.711} \times 0.995^{\text{age}} \times 0.969$ if female $\times 1.08$ if Black   $\alpha = -0.248$ (female); $-0.207$ (male); $\kappa = 0.7$ (female); $\kappa = 0.9$ (male)	Improved precision and accuracy vs CKD-EPI eGFR <sub>cr</sub> and eGFR <sub>cys</sub> ; recommended in adults as confirmatory test
Pediatric	CKiD eGFR <sub>cr-cys</sub> (2012) <sup>h</sup>	Plasma clearance of iothexol	No	389 boys/254 girls; mGFR 43 mL/min/1.73 m <sup>2</sup>	$39.8 \times (\text{height}/\text{Scr})^{0.456} \times (1.8/\text{Scys})^{0.418} \times (30/\text{SUN})^{0.079} \times (1.076^{\text{male}}) \times (\text{height in m}/1.4)^{0.179}$	Iothexol measurements have since been recalibrated; cystatin C assay not standardized

**Table S1** displays equations developed by other research groups. Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CKiD, Chronic Kidney Disease in Children; eGFR, estimated glomerular filtration rate; eGFR<sub>cr</sub>, eGFR from creatinine; eGFR<sub>cr-cys</sub>, eGFR from a combination of creatinine and cystatin C; eGFR<sub>cys</sub>, eGFR from cystatin C; mCL<sub>cr</sub>, measured creatinine clearance; MDRD, Modification of Diet in Renal Disease; mGFR, measured glomerular filtration rate; Scr, serum creatinine (in mg/dL); Scys, serum cystatin C (in mg/L); SUN, serum urea nitrogen.

<sup>a</sup>Cockcroft and Gault, 1976 (*Nephron*. <https://doi.org/10.1159/000180580>).

<sup>b</sup>Levey et al, 2006 (*Ann Intern Med*. <https://doi.org/10.7326/0003-4819-145-4-200608150-00004>).

<sup>c</sup>Levey et al, 2009 (*Ann Intern Med*. <https://doi.org/10.7326/0003-4819-150-9-200905050-00006>); published correction appears at <https://doi.org/10.7326/0003-4819-155-6-201109200-00024>.

<sup>d</sup>Schwartz et al, 2009 (*J Am Soc Nephrol*. <https://doi.org/10.1681/asn.2008030287>).

<sup>e</sup>Ng et al, 2018 (*Kidney Int*. <https://doi.org/10.1016/j.kint.2018.01.034>).

<sup>f</sup>Pierce et al, 2021 (*Kidney Int*. <https://doi.org/10.1016/j.kint.2020.10.047>).

<sup>g</sup>Inker et al, 2012 (*N Engl J Med*. <https://doi.org/10.1056/nejmoa1114248>).


<sup>h</sup>Schwartz et al, 2012 (*Kidney Int*. <https://doi.org/10.1038/ki.2012.169>).

However all these equations estimating GFR are based on population with a large representation of North Americans

# Relative performance of *eGFR* vs *mGFR*


- The accuracy of GFR estimating equations is expressed as P<sub>30</sub>, the percentage of eGFR values within 30% of the measured GFR

Estimating equation	Measured GFR reference methods	P <sub>30</sub> (95% CI) (%)
MDRD <sup>16</sup>	iothalamate	80.6 (79.5–82.0)
CKD-EPI creatinine <sup>16</sup>	iothalamate	84.1 (83.0–85.3)
CKD-EPI cystatin C <sup>17</sup>	iothalamate, iohexol, EDTA	84.2 (82.0–86.2)
CKD-EPI creatinine + cystatin C <sup>17</sup>	iothalamate, iohexol, EDTA	91.9 (90.2–93.4)
Targeted metabolite panel estimated GFR <sup>18</sup>	iothalamate, iohexol	96.3 (development) 98.1 (validation)



- Within-subject biological variation:
  - Similar in mGFR and eGFR
  - no disadvantage to the use of simple estimates of GFR when monitoring patients over time

GFR measure or estimate	Within-subject biological variation (95% CI) (%)
iohexol	6.7 (5.6–8.2)
MDRD	5.0 (4.3–6.1)
CKD-EPI creatinine	5.3 (4.5–6.4)
CKD-EPI cystatin C	5.3 (4.5–6.5)
CKD-EPI creatinine + cystatin C	5.0 (4.3–6.2)



# When to prefer « mGFR » instead of « eGFR »?

- **In clinical scenarios and conditions where the use of creatinine-based estimating equations may not be valid...**
  - Regardless of the specific equation, the accuracy of eGFR<sub>cr</sub> or eGFR<sub>cys</sub> are limited by variation in GFR determinants of serum creatinine or cystatin that are not captured by the demographic and clinical variables.
- **To guide critical clinical decisions....**
  - Drugs with narrow therapeutic index
  - Kidney donation...

The ***Kidney Disease Improving Global Outcomes (KDIGO)*** guidelines suggest measuring the glomerular filtration rate (GFR) using an exogenous filtration marker 'under circumstances in which **more accurate** ascertainment of GFR will impact **treatment decisions**

The ***European Medicines Agency (EMA)*** recommend that a method that accurately measures GFR using an exogenous marker should be used in **pharmacokinetic studies** in subjects with decreased kidney function.



# Effect of body composition

- eGFR equations were developed and validated in individuals with predominantly « *normal* » **body composition**.
- Therefore eGFR equations are « not validated » in many special circumstances...
  - Extreme body composition
    - Reduction in muscle mass
    - Obesity


# Reduction in muscle mass

- Creatinine originates from muscle metabolism

- Sarcopaenia
- Anorexia nervosa
- Muscle dystrophy
- Limb amputation
- Neuromuscular disease
- Paraplegia
- Spina bifida
- Cachexia
- Malignancy
- Chronic inflammatory disease

→ serum creatinine concentrations are lower


→ eGFR falsely elevated (when based on serum creatinine)



- Cystatin C has been shown to have greater accuracy in these conditions but is still inferior to **mGFR**

# Obesity

- Obesity prevalence is increasing worldwide
- $eGFR_{cr}$  equations may overestimate GFR
  - Reduced muscle mass
- $eGFR_{cys}$  equation underestimates GFR
  - Positive association between cys C and greater fat mass.
  - Indexation to body surface area (BSA) instead of  $1.73m^2$  may provide more accurate estimation of GFR ?
- Due to the discordant bias of both equations, the combined  $eGFR_{cre+cysC}$  CKD-EPI equation yielded the least bias and was suggested as the most suitable equation in this setting



- **Almost all  $eGFR$  equations report GFR results indexed to the 'average' BSA of  $1.73m^2$ , which can lead to further systematic incorrectness**
- Use **mGFR** when critical decisions have to be made regarding treatment in advanced CKD:
- dosing of potentially nephrotoxic drugs/ with a narrow therapeutic index and critical renal elimination.**


# « Race »

- The CKD-EPI equations offer a version (2009 ><2012) where « race » is integrated as a coefficient for *African Americans*.
  - Applying the CKD- EPI race equation leads to 'corrected', (higher GFR) values in Black
  - Blacks had a systematically 16-20% higher serum creatinine compared with white patients at a similar mGFR (MDRD and CKD-EPI datasets)
  - Finding was thought to reflect biological differences related to non-GFR determinants of serum creatinine
    - Greater muscle mass in Blacks ? Probably not only...
    - The cause of the higher serum creatinine in the Black individuals is not well understood
      - Tubular secretion or creatinine generation.



# « Race »

- However, the construct of « race » is problematic for several reasons...
  - There is no biological ground for race
  - The « race coefficient » ignores the substantial variability among Black patients... There is no « African American prototype »



- In a pair-matched analysis of 604 African Europeans and White Europeans from the Nephro Test cohort, serum creatinine in African Europeans was only 8% higher as compared with White patients at a similar mGFR
- The CKD-EPI race equation does not perform well in black living outside the USA (Congo and Ivory Coast)
- There are also questions whether coefficients for eGFR<sub>cr</sub> for race or *ethnic groups* other than Black people are required.
  - Asian ?
  - In Japan, a modified CKD-EPI creatinine equation is used that applies a correction factor of 0.813


# « Race »

## Should we eliminate the term for « Black race » when using eGFR equations ?

- *Its removal would lead to lower eGFR in some patients who self-identify as Black...*
  - For example, if a 60-year-old man had a creatinine level of 1.0 mg/dL, he would have a eGFR<sub>cr</sub> of 94 mL/min/1.73 m<sup>2</sup> if he self-identified as Black and a eGFR<sub>cr</sub> of 81 mL/min/ 1.73 m<sup>2</sup> if he self-identified as White.
  - Advantages of « lower eGFR »
    - Earlier care for CKD
    - Earlier kidney transplant evaluations.
  - Disadvantages
    - Decrease the use of some medications ie chemotherapy
    - Insurance more expensive
    - Decrease acceptance of kidney donor candidates
- **Better methods are needed to improve the accuracy of GFR assessment without requiring specification of race (mGFR)**

# AKI

- An acute change in GFR would cause any serum levels of endogenous filtration markers to be in nonsteady state, with a **lag** until the serum levels increase to match the change in GFR. The converse is true for recovery from AKI.





# Liver cirrhosis




- The inaccuracy of MDRD or CKD-EPI equations in cirrhosis is well described
- Significant overestimation of the GFR
- Due to the presence of non-GFR determinants that affect serum creatinine concentration
  - Decreased muscle mass
  - Malnutrition
  - Hepatic dysfunction
  - Bilirubin → interference with creatinine assay
- Better GFR estimation using cystatin C ?
  - Potential liver transplant recipients
  - Urinary inulin clearance as the gold-standard mGFR
  - CKD-EPI<sub>cys</sub> equation underestimated the mGFR by 4 mL/min/1.73 m<sup>2</sup>
  - CKD-EPI<sub>cr</sub> equation overestimated the mGFR by 18.4 mL/min/ 1.73 m<sup>2</sup>.
  - 83 % of CKD-EPI<sub>cys</sub> estimates were within 30% of the inulin mGFR versus only 56% of CKD-EPI<sub>cr</sub> estimates
- Other studies have not demonstrated the superiority of CKD-EPI<sub>cys</sub> in cirrhotic patients

→ Clinical indications for **mGFR measurement** in cirrhosis include :  
medication dosing

the assessment of potential **combined liver–kidney transplantation**.

Cystatin C–based equations may be considered as a reasonable alternative.

# Evaluation of living kidney donor




- Evaluation of GFR is a cornerstone in the management of living kidney donors
  - Before and after Tx (follow-up after donation)
- GFR assessment must provide robust results to authorize donation safely
  - Guidelines recognize mGFR as the gold standard (however not mandatory...)
- The question of whether to use eGFR or mGFR significantly impacts the decision to authorize donation
  - In a cohort of 2733 potential living kidney donors in France, creatinine-based eGFR and mGFR were discordant in 26% of the candidates at the threshold of 90mL/min/ 1.73 m<sup>2</sup>.
  - Poor performance in older donor, lower GFR, obese donor
  - → higher risk of subsequent end-stage kidney disease
- **mGFR** should be encouraged in the evaluation of living kidney donor

# Patients with cancer

- Cachectics/ sarcopenics
- Older patients
- Unstable body weight
- Liver disease
- At high risk of AKI
- Treated with chemotherapeutic agents with a narrow therapeutic index
  - Excreted by the kidney
  - Overdosing with secondary effects (AKI or other...)
  - Underdosing with an ineffective treatment with therapeutic failure and relapse

→ Thus, in this specific population, a **precise assessment of GFR** is particularly important



# Take home messages

- Glomerular filtration is only one of the many functions of the kidney.
- No « strict » correlation between GFR and renal mass
  - Hyperfiltration and AKI due to functional cause (hypoperfusion)
- Creatinine and cystatine C are the most widely marker used to estimate GFR
  - These markers have many pitfalls and are imprecise
  - It is not possible to estimate GFR during AKI with creatinine
- Situation when it is important to estimate **accurately** renal function are limited
  - To guide critical clinical decisions where eGFR equation perform poorly
    - Drugs with narrow therapeutic index (chemotherapy)
    - Kidney donor evaluation
  - Research purpose
  - When there is discrepancy between clinic and eGFR (CKD-EPI)
- Creatinine + cystatine C (CKD-EPI<sub>cys-Cr</sub>) based equations should be encouraged